Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma

Sadakatsu Ikeda, Donna E. Hansel, Razelle Kurzrock

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations

Abstract

Advanced urothelial carcinoma is frequently lethal, and improvements in cytotoxic chemotherapy have plateaued. Recent technological advances allows for a comprehensive analysis of genomic alterations in a timely manner. The Cancer Genome Atlas (TCGA) study revealed that there are numerous genomic aberrations in muscle-invasive urothelial carcinoma, such as TP53, ARID1A, PIK3CA, ERCC2, FGFR3, and HER2. Molecular targeted therapies against similar genetic alterations are currently available for other malignancies, but their efficacy in urothelial carcinoma has not been established. This review describes the genomic landscape of malignant urothelial carcinomas, with an emphasis on the potential to prosecute these tumours by deploying novel targeted agents and immunotherapy in appropriately selected patient populations.

Original languageEnglish (US)
Pages (from-to)699-706
Number of pages8
JournalCancer Treatment Reviews
Volume41
Issue number8
DOIs
StatePublished - Sep 1 2015
Externally publishedYes

Keywords

  • Genetic aberrations
  • Immune therapy
  • Targeted therapy
  • Urothelial carcinoma

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint

Dive into the research topics of 'Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma'. Together they form a unique fingerprint.

Cite this